

SSc-ILD Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes

DelveInsight's SSc-ILD Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NV, UNITED STATES,
February 13, 2025 /EINPresswire.com/

--
DelveInsight's "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the

Systemic Sclerosis-associated Interstitial Lung Disease, historical and forecasted epidemiology as well as the Systemic Sclerosis-associated Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Systemic Sclerosis-associated Interstitial Lung Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [SSc-ILD Market Forecast](#)

Some of the key facts of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report:

- The Systemic Sclerosis-associated Interstitial Lung Disease market size was valued approximately USD 750 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In February 2025, Boehringer Ingelheim's lung disease drug, nerandomilast, demonstrated success in a Phase III trial, positioning the company to seek approval for its use in a second condition. Topline results from the Phase III FIBRONEER-ILD trial (NCT05321082) showed that nerandomilast improved lung function in patients with progressive fibrosing interstitial lung diseases (PF-ILDs), excluding idiopathic pulmonary fibrosis (IPF). Previously, Boehringer conducted a separate IPF trial, which supported its new drug application (NDA) submission last year. The company's Ofev remains the standard of care (SOC) and is one of only two approved



SSc-ILD Market Trends

treatments for IPF. It is also approved for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic interstitial lung diseases.

- In November 2024, Zura Bio Limited (Nasdaq: ZURA), a clinical-stage immunology company focused on developing innovative dual-pathway antibodies for autoimmune and inflammatory diseases, has submitted a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). The submission is for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody that targets both IL-17A and BAFF, for the treatment of systemic sclerosis (SSc) in adults.
- In June 2024, MDI Therapeutics has initiated dosing in a Phase I trial to advance the development of a potential treatment for systemic sclerosis (SSc) and interstitial lung disease (ILD). The study's primary objective is to evaluate the safety and tolerability of MDI-2517, an investigational inhibitor targeting plasminogen activator inhibitor 1 (PAI-1).
- The existing pipeline for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) includes prospective drugs with the potential to impact market dynamics. PRA023, Belimumab (GSK1550188), Vixarelimab (KPL-716), and several others are among the prominently featured drugs for this indication.
- The collective diagnosed prevalent population of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the 7MM reached approximately 53,178 in 2022. There is an anticipated substantial increase in these cases at a notable Compound Annual Growth Rate (CAGR) over the study period from 2020 to 2034.
- Within the European countries, the United Kingdom exhibited the highest number of diagnosed prevalent cases of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), totaling around 4,269 cases in 2022. Italy and France followed closely in the same year. In contrast, Germany had the lowest diagnosed prevalent population in that specific year.
- According to the analysis, it has been noted that the age group with the highest number of diagnosed patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) is 65 and above, while the lowest incidence is observed in the 0-18 age group.
- Key Systemic Sclerosis-associated Interstitial Lung Disease Companies: Prometheus Biosciences, Inc., MERCK, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, and others
- Key Systemic Sclerosis-associated Interstitial Lung Disease Therapies: PRA023, Belimumab, Vixarelimab, MK-2225 (ACE-1334), Nintedanib, bosentan, Belimumab, Cyclophosphamide, GenSci048, and others
- The Systemic Sclerosis-associated Interstitial Lung Disease epidemiology based on gender analyzed that females are more likely to get affected by SSc-ILD in comparison to male
- The Systemic Sclerosis-associated Interstitial Lung Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Sclerosis-associated Interstitial Lung Disease pipeline products will significantly revolutionize the Systemic Sclerosis-associated Interstitial Lung Disease market dynamics.

Systemic Sclerosis-associated Interstitial Lung Disease Overview

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) is a complication associated with

systemic sclerosis (SSc), also known as scleroderma. Systemic sclerosis is a chronic autoimmune connective tissue disorder characterized by abnormal immune system activity, vascular problems, and excessive collagen deposition in the skin and other organs.

Get a Free sample for the Systemic Sclerosis-associated Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=einpressswire&utm_medium=pressrelease&utm_campaign=gpr

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology Segmentation:

The Systemic Sclerosis-associated Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- Total Prevalence of Systemic Sclerosis-associated Interstitial Lung Disease
- Prevalent Cases of Systemic Sclerosis-associated Interstitial Lung Disease by severity
- Gender-specific Prevalence of Systemic Sclerosis-associated Interstitial Lung Disease
- Diagnosed Cases of Episodic and Chronic Systemic Sclerosis-associated Interstitial Lung Disease

Download the report to understand which factors are driving Systemic Sclerosis-associated Interstitial Lung Disease epidemiology trends @ [SSc-ILD Epidemiology Forecast](#)

Systemic Sclerosis-associated Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Sclerosis-associated Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Systemic Sclerosis-associated Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Systemic Sclerosis-associated Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Systemic Sclerosis-associated Interstitial Lung Disease Therapies and Key Companies

- PRA023: Prometheus Biosciences, Inc./ MERCK
- Belimumab: GlaxoSmithKline
- Vixarelimab: Genentech, Inc.
- MK-2225 (ACE-1334): Acceleron/ MERCK
- Nintedanib: Boehringer Ingelheim
- bosentan: Actelion
- Belimumab: GlaxoSmithKline
- Cyclophosphamide: Hôpital Claude-Huriez
- GenSci048: Changchun GeneScience Pharmaceutical

Systemic Sclerosis-associated Interstitial Lung Disease Market Strengths

- The shortfall of therapeutic candidates in the emerging pipeline as well as in the market can give an advantage to emerging therapy to gain huge market share with lesser competition.

Systemic Sclerosis-associated Interstitial Lung Disease Market Opportunities

- The scarcity of approved treatment options offers a great opportunity for the investment and development of novel therapies.

Scope of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Systemic Sclerosis-associated Interstitial Lung Disease Companies: Prometheus Biosciences, Inc., MERCK, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, and others
- Key Systemic Sclerosis-associated Interstitial Lung Disease Therapies: PRA023, Belimumab, Vixarelimab, MK-2225 (ACE-1334), Nintedanib, bosentan, Belimumab, Cyclophosphamide, GenSci048, and others
- Systemic Sclerosis-associated Interstitial Lung Disease Therapeutic Assessment: Systemic Sclerosis-associated Interstitial Lung Disease current marketed and Systemic Sclerosis-associated Interstitial Lung Disease emerging therapies
- Systemic Sclerosis-associated Interstitial Lung Disease Market Dynamics: Systemic Sclerosis-associated Interstitial Lung Disease market drivers and Systemic Sclerosis-associated Interstitial Lung Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Systemic Sclerosis-associated Interstitial Lung Disease Unmet Needs, KOL's views, Analyst's views, Systemic Sclerosis-associated Interstitial Lung Disease Market Access and Reimbursement

To know more about Systemic Sclerosis-associated Interstitial Lung Disease companies working

in the treatment market, visit @ [SSc-ILD Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Systemic Sclerosis-associated Interstitial Lung Disease Market Report Introduction
2. Executive Summary for Systemic Sclerosis-associated Interstitial Lung Disease
3. SWOT analysis of Systemic Sclerosis-associated Interstitial Lung Disease
4. Systemic Sclerosis-associated Interstitial Lung Disease Patient Share (%) Overview at a Glance
5. Systemic Sclerosis-associated Interstitial Lung Disease Market Overview at a Glance
6. Systemic Sclerosis-associated Interstitial Lung Disease Disease Background and Overview
7. Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Systemic Sclerosis-associated Interstitial Lung Disease
9. Systemic Sclerosis-associated Interstitial Lung Disease Current Treatment and Medical Practices
10. Systemic Sclerosis-associated Interstitial Lung Disease Unmet Needs
11. Systemic Sclerosis-associated Interstitial Lung Disease Emerging Therapies
12. Systemic Sclerosis-associated Interstitial Lung Disease Market Outlook
13. Country-Wise Systemic Sclerosis-associated Interstitial Lung Disease Market Analysis (2020–2034)
14. Systemic Sclerosis-associated Interstitial Lung Disease Market Access and Reimbursement of Therapies
15. Systemic Sclerosis-associated Interstitial Lung Disease Market Drivers
16. Systemic Sclerosis-associated Interstitial Lung Disease Market Barriers
17. Systemic Sclerosis-associated Interstitial Lung Disease Appendix
18. Systemic Sclerosis-associated Interstitial Lung Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/785803536>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.